ClinicalTrials.gg
RecruitingNCT06122987Updated May 23, 2024

Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock

A Phase 4 interventional study of Angiotensin II and hydrocortisone sodium succinate in Septic Shock, Shock and Sepsis, sponsored by Kingman Regional Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-23.

Sponsored by Kingman Regional Medical Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing Angiotensin II in Shock, Septic — 4 open to participants now, 5 under way, none of them phase 3. Angiotensin II · Shock, Septic.

Planned enrollment
3rd of 12
50 · median 30
Started
2023
with 1 other
Phase 4
6 of 12
3 open now
Registered
8th of 12
by date
Lead sponsor
1 of 12
Kingman Regional Medical Center

Among the 12 studies testing Angiotensin II in Shock, Septic, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2023, is one of 6 in phase 4, and was the 8th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

4 of the 12 studies testing Angiotensin II in Shock, Septic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Angiotensin II

Angiotensin II: first FDA approval 2017 (GIAPREZA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Angiotensin II in Shock, Septic, or all of them as a file.
02

Study summary

Norepinephrine is a catecholamine that is the first-line vasopressor for septic shock. The addition of non-catecholamine vasopressors, including vasopressin and angiotensin-II may be used in adults with septic shock that have inadequate mean arterial pressure while on norepinephrine. Uncertainty exists regarding the timing of initiation of these agents and there is a lack of data comparing their safety and efficacy.

The current literature suggests that earlier initiation of angiotensin-II will have a more significant reduction on norepinephrine-equivalent dose compared to later initiation. In addition, approximately half of patients initiated on vasopressin do not have an early hemodynamic response 6 hours after initiation. The purpose of this study is to evaluate the efficacy of angiotensin-II when used as the second vasopressor agent for septic shock.

Read the detailed description

Objectives:

Primary Objective:

  1. To evaluate the efficacy of ang-II when used as the second vasopressor agent for septic shock

Secondary Objectives:

  1. To assess the duration of response to ang-II
  2. To assess overall survival
  3. To assess the amount of time spent in the ICU
  4. To assess the need for renal replacement therapy
  5. To assess the overall duration of vasoactive medication use
  6. To assess toxicity and tolerability
03

Conditions studied

  • Septic Shock
  • Shock
  • Sepsis
  • Systemic Inflammatory Response Syndrome

Keywords

  • Sepsis
  • Angiotensin II
  • Hydrocortisone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients admitted to the ICU within 12 hours of presentation to the emergency department for septic shock requiring 15-25 mcg/min of norepinephrine. Septic shock will be defined as having a known or presumed infection with two or more criteria of systemic inflammatory response syndrome, a mean arterial pressure \<65 mm Hg despite fluid resuscitation requiring vasopressor support, and a serum lactate >2 mmol/L. Criteria of systemic inflammatory response syndrome include a temperature >100.4°F or \<96.8°F; heart rate >90/min; respiratory rate >20/min and a white blood cell count >12,000/mm3 or \<4,000/mm3.

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Pregnancy or lactation
  • Known allergic reactions to angiotensin-II or hydrocortisone sodium succinate
  • Requiring >25 mcg/min of norepinephrine or on any vasopressor other than norepinephrine at study enrollment
  • bleeding precluding the use of chemical prophylaxis for venous thromboembolism
  • Treatment with another drug or other intervention during study timeframe
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Single Arm

    Drug: Angiotensin II Other Names: Giapreza

    Drug: Angiotensin II and hydrocortisone sodium succinate

Interventions

06

What researchers measure

Primary outcomes

  1. The incidence of hemodynamic response, defined as a decrease in norepinephrine-equivalent dose with a MAP ≥65 mm Hg at 1 hour after initiation of angiotensin-II

    Defined as a decrease in norepinephrine-equivalent dose with a MAP ≥65 mm Hg at 1 hour after initiation of angiotensin-II.

    Time frame: 1 hour

Secondary outcomes

  1. The incidence of hemodynamic response at 3 hours after initiation of angiotensin-II

    Defined as a decrease in norepinephrine-equivalent dose with a MAP ≥65 mm Hg at 3 hours after initiation of angiotensin-II.

    Time frame: 3 hours

  2. The incidence of hemodynamic response at 6 hours after initiation of angiotensin-II

    Defined as a decrease in norepinephrine-equivalent dose with a MAP ≥65 mm Hg at 6 hours after initiation of angiotensin-II.

    Time frame: 6 hours

  3. 28-day mortality

    Defined as all cause mortality up to 28 days from study enrollment.

    Time frame: 28 days

  4. ICU length of stay

    Defined as the time spent within the ICU until discharge to a step down unit.

    Time frame: 1 year

  5. Need for renal replacement therapy

    Defined as patients started on either continuous renal replacement therapy (CRRT) or intermittent hemodialysis (IHD) during the study period.

    Time frame: 1 year

  6. Vasoactive medication duration overall

    Defined as the duration (hours) of vasoactive medication use during the study period.

    Time frame: 1 year

  7. Incidence of adverse reactions

    Define as an unexpected or unintended effect suspected to be caused by a medicine.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2024, 12 months after the start.

Of 39 non-industry phase 4 interventional studies under Shock, Septic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 38. This study's planned 12 months is below that.

Counting every sponsor, half of 40 studies reached it within 24 months; a quarter within 16 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2023
First posted
Nov 8, 2023
StartActual
Dec 4, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Jan 2025
Last update
May 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06122987
Lead sponsor
Kingman Regional Medical Center
Collaborators
La Jolla Pharmaceutical Company
Responsible party
Tyson Dietrich (Pharmacist, Kingman Regional Medical Center) — Principal investigator
First posted
Nov 8, 2023
Start date
Dec 4, 2023
Primary completion
Dec 2024 (estimated)
Completion
Jan 2025 (estimated)
Last update
May 23, 2024

Study contacts

Tyson Dietrich, PharmD
Contact
TDietrich@azkrmc.com
928-263-3933
Anthony Santarelli, PhD
Contact
anthony.santarelli@azkrmc.com
928-757-0649 ext. 5143
Tyson Dietrich, PharmD
principal investigator · Kingman Regional Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Angiotensin II · Hydrocortisone hemisuccinate

Start the discussion